Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of cytomegalovirus, adenovirus and Epstein-Barr virus antigens
- Development stage
- Phase 3
- Lead developer
- Miltenyi Biotec
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic multi-virus-specific T-cell therapy developed by the University Medical Center Freiburg. It consists of donor-derived CD4+ and CD8+ T lymphocytes that have been stimulated ex vivo with synthetic peptide pools (PepMix) representing antigens from Cytomegalovirus (CMV), Adenovirus (AdV), and Epstein-Barr Virus (EBV). The therapy is designed to restore virus-specific immunity in immunocompromised patients, particularly those who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and suffer from refractory viral infections. By providing a broad repertoire of T cells targeting multiple viral epitopes, it aims to control viral replication and prevent clinical disease.
- Other names
- Multi-virus-specific T-cellsMVSTtrivirus-specific T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)Cytomegalovirus immediate-early protein 1-derived peptide-human leukocyte antigen complexCytomegalovirus pp65-derived peptide-HLA complexesEpstein-Barr virus BZLF1-derived peptide-HLA complexesEpstein-Barr virus nuclear antigen family-derived peptide-human leukocyte antigen complexesEpstein-Barr virus latent membrane protein 1 and 2-derived peptide-human leukocyte antigen complexes
Beyond the preview
Go deeper on allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of cytomegalovirus, adenovirus and Epstein-Barr virus antigens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of cytomegalovirus, adenovirus and Epstein-Barr virus antigens.